Toshihiko Hibino Selected Research

Neoplasms (Cancer)

1/2019	exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.
1/2019	Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
1/2019	Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.
4/2018	β-1,3-Galactosyl-O-Glycosyl-Glycoprotein β-1,6-N-Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer Motility.
1/2016	MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.
8/2014	DNAX-activating protein 10 (DAP10) membrane adaptor associates with receptor for advanced glycation end products (RAGE) and modulates the RAGE-triggered signaling pathway in human keratinocytes.
2/2006	Chemical peeling by SA-PEG remodels photo-damaged skin: suppressing p53 expression and normalizing keratinocyte differentiation.
7/2002	Aberrant expression of serpin squamous cell carcinoma antigen 2 in human tumor tissues and cell lines: evidence of protection from tumor necrosis factor-mediated apoptosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshihiko Hibino Research Topics

Disease

8	Neoplasms (Cancer) 01/2019 - 07/2002
7	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2013
6	Inflammation (Inflammations) 04/2018 - 02/2010
5	Atopic Dermatitis (Atopic Eczema) 05/2021 - 02/2011
5	Melanoma (Melanoma, Malignant) 01/2019 - 01/2013
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 01/2002
3	Psoriasis (Pustulosis Palmaris et Plantaris) 08/2018 - 01/2002
2	Rheumatoid Arthritis 01/2023 - 03/2020
2	Parakeratosis 02/2011 - 02/2010
2	Alopecia (Baldness) 06/2004 - 06/2003
1	Injection Site Reaction 01/2023
1	Thymoma (Thymic Carcinoma) 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Skin Diseases (Skin Disease) 05/2008

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2002
4	CytokinesIBA 01/2019 - 05/2008
3	LigandsIBA 01/2019 - 01/2013
3	CD146 AntigenIBA 01/2019 - 04/2018
2	Etanercept (Enbrel)FDA Link 01/2023 - 03/2020
2	Biosimilar PharmaceuticalsIBA 01/2023 - 03/2020
2	bleomycin hydrolaseIBA 05/2021 - 03/2011
2	TNF Receptor-Associated Factor 2 (TRAF2)IBA 01/2019 - 11/2016
2	Cell Surface ReceptorsIBA 01/2019 - 01/2016
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 01/2019
2	Basigin (Extracellular Matrix Metalloproteinase Inducer (EMMPRIN))IBA 04/2018 - 01/2013
2	Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA 04/2018 - 01/2016
2	Metalloproteases (Metalloproteinases)IBA 11/2016 - 01/2013
2	Caspase 14IBA 01/2014 - 02/2011
2	Peptide Hydrolases (Proteases)FDA Link 03/2013 - 07/2002
2	Filaggrin ProteinsIBA 03/2013 - 03/2011
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2008 - 07/2002
2	CaspasesIBA 06/2004 - 06/2003
2	AntigensIBA 07/2002 - 01/2002
2	squamous cell carcinoma-related antigenIBA 07/2002 - 01/2002
2	SerpinsIBA 07/2002 - 01/2002
1	trichohyalinIBA 01/2020
1	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Neutralizing AntibodiesIBA 01/2019
1	Fc Receptors (Fc Receptor)IBA 01/2019
1	matrix metalloproteinase 25IBA 01/2019
1	InflammasomesIBA 08/2018
1	NucleotidesIBA 08/2018
1	Heparitin Sulfate (Heparan Sulfate)IBA 01/2016
1	Cell Adhesion MoleculesIBA 01/2016
1	Receptor for Advanced Glycation End ProductsIBA 08/2014
1	Matrix Metalloproteinases (MMPs)IBA 01/2013
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2013
1	Calcium-Binding ProteinsIBA 01/2013
1	EnzymesIBA 02/2011
1	Biomarkers (Surrogate Marker)IBA 02/2010
1	Therapeutic UsesIBA 02/2010
1	Interleukin-6 (Interleukin 6)IBA 05/2008
1	Salicylic Acid (2 Hydroxybenzoic Acid)FDA LinkGeneric 02/2006
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 02/2006
1	AndrogensIBA 06/2004
1	Transforming Growth Factor beta2IBA 06/2004
1	Cholestenone 5 alpha-Reductase (5 alpha-Reductase)IBA 06/2004
1	Testosterone (Sustanon)FDA Link 06/2004
1	Transforming Growth Factor beta (TGF-beta)IBA 06/2003
1	Messenger RNA (mRNA)IBA 07/2002

Therapy/Procedure

2	Therapeutics 01/2019 - 04/2018